Panel discussion

Experienced dealmakers discuss how to create value through business development in an adverse financing environment.
Dr. Jullian Jones is CBO at Monte Rosa, a clinical-stage company developing molecular glue degraders. At Eli Lilly, she previously worked on the $8 billion acquisition of Loxo Oncology.
Dr. Corinne Savill is CBO at Cullinan Oncology, a clinical-stage cancer therapeutics firm. She previously led Business Development and Licensing at Novartis Pharma.
Dr. Jens Hennecke is CBO of Sotio Biotech, a clinical-stage immunotherapy company. He previously worked at Micromet on their $1.2 billion acquisition by Amgen.